Introduction
Bendamustine fi rst demonstrated promising activity in non-Hodgkin lymphoma (NHL) over 30 years ago. First synthesized in 1963 in the German Democratic Republic, 1 the intention was to create an agent with less toxicity that would retain the effi cacy of nitrogen mustard compounds. While used extensively in Germany for several years, bendamustine was not approved for use in the United States until 2008.
Bendamustine is a chemotherapeutic agent that is structurally similar to both alkylating agents and antimetabolites. However, in vivo and in vitro studies have demonstrated an incomplete cross-resistance with other alkylating agents such as cyclophosphamide, melphalan, and carmustine. 2 A benzimidazole ring system may confer nucleosidelike properties and provide stability that correlates with longer-lasting DNA damage by bendamustine. 2 Additionally, in- creased stability has been noted when compared to other nitrogen mustards, along with slower repair of DNA damage than with other alkylating agents. 2 Phase II studies in East Germany were conducted with bendamustine in a small group of patients diagnosed with chronic lymphocytic leukemia (CLL). [3] [4] [5] [6] These initial studies demonstrated response rates of 65% to 93% and a favorable adverse event profi le. A European intergroup CLL study later reported the superiority of bendamustine over chlorambucil as fi rst-line treatment in CLL patients. 7 Overall response rates (ORRs) in 156 patients receiving bendamustine and 149 patients receiving chlorambucil were 68% and 39%, respectively. Additionally, median progression-free survival (PFS) was 21.7 months in patients treated with bendamustine vs 9.3 months in patients treated with chlorambucil. The median duration of remission was 18.9 months and 6.1 months, respectively. The results of this trial led to approval of bendamustine by the US Food and Drug Administration for the treatment of CLL.
The effi cacy of bendamustine in NHL was also demonstrated in two North American trials that reported responses in chemotherapy and rituximabrefractory NHL at greater than 70%. 7, 8 It has also been shown to be effi cacious in patients with follicular and mantle cell lymphoma, with response rates of 90% to 92% and complete remission rates of 55% to 60% when utilized in combination with rituximab. 9, 10 Bendamustine is associated with several adverse effects, including significant infusion-related reactions (IRRs). Clinical trials report IRRs of all grades for fever of 24% to 34% (2% grade 3/4), chills 1% to 14% (0% to 1% grade 3/4), pruritus 6% (0% grade 3/4), and rash 5% to 16% (1% to 3% grade 3/4). [8] [9] [10] An IRR was defi ned as a disorder characterized by adverse reaction to the infusion of pharmacological or biological substances according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. While these reactions are well documented, there is no consensus on the optimal premedication regimen for The primary objective was to assess patient tolerance of bendamustine infusion with designated premedications and effi cacy of the current premedication regimen employed at our center with regard to the occurrence of IRRs. Secondary objectives included determination of the hospital admission rate, incidence of febrile neutropenia (FN), incidence of neutropenia and resulting growth factor use, discontinuation rate, and reasons for discontinuation. A retrospective review of electronic medical records was used to obtain necessary demographic, clinical, and laboratory data. Demographic data collected included age, height, weight, body surface area, and gender. Clinical and laboratory data collected included baseline laboratory values, primary diagnosis, dosing, the number of doses received, concurrent rituximab use if applicable, growth factor utilization, premedication administration, as well as safety data including the rate of adverse reactions, interventions, and hospitalization. Data specifi c to IRR were found in outpatient nursing notes documenting any adverse events occurring throughout the infusion time. The data were coded and extracted for analysis using SPSS version 17.0. Data were analyzed using descriptive statistics.
Results
Seventy-three patients received a total of 478 infusions of bendamustine. Baseline patient characteristics are summarized in the Table. Adherence to dexamethasone and ondansetron as premedications was 97.7% and 99.5%, respectively. Overall there were 41 reports of nonhematologic adverse reactions in 34 of the 73 patients (46.5%).
Infusion-Related Reactions
IRRs affected 19% of our population. Our analysis revealed that 82% of IRRs occurred in the fi rst cycle of bendamustine/rituximab regimen. More importantly, 100% of IRRs were attributed directly to the concurrent rituximab infusion and no IRRs occurred in patients receiving bendamustine alone. In comparison to available data from the manufacturer, the frequency of IRRs at our center is lower in terms of fever (22% vs 36% to 59%), chills (6.8% vs 9%), rash (11% vs 12%), and pruritus (2.5% vs 8%).
8 Based on these data, the premedication regimen with ondansetron and dexamethasone appears to be effective in the prevention of IRRs occurring with the administration of bendamustine.
Adverse Reactions
Thirty-four patients (46.5%) experienced a nonhematologic adverse reaction during treatment with bendamustine. Approximately half of the reactions occurred with the fi rst cycle of bendamustine and could be directly attributed to rituximab administration. After accounting for rituximab-related infusions, only 19 patients (26%) experienced a nonhematologic adverse reaction to bendamustine. Fever was the most common adverse reaction reported, affecting 22% of the overall population (Fig  1) . However, only 10.9% of our patients experienced FN, which is less than the proportion reported in previous studies.
A total of 35 patients received colony-stimulating factors during treatment with bendamustine (Fig 2) . They were utilized as primary prophylaxis for neutropenia in 35.6% of patients (32.9% received pegfi lgrastim and 2.7% received the prevention of these adverse effects. At Moffi tt Cancer Center, we utilize a regimen of ondansetron 16 mg orally and dexamethasone 10 mg IV push prior to each bendamustine infusion. This regimen was chosen secondary to the moderately emetogenic potential of bendamustine. Appropriate premedication is vital to improving the quality of care and avoiding unnecessary adverse effects with bendamustine infusions. Similarly, it is important to avoid additional and unnecessary premedications in an effort to avoid IRRs. Herein, we describe our experience with our premedication regimen and the adverse effects of bendamustine infusions.
Methods
The study design was a retrospective chart review. We identifi ed 73 consecutive patients who received 478 bendamustine infusions from April 2008 through June 2010 at our center, and a retrospective analysis was performed. Standard premedications for patients receiving bendamustine infusions were ondansetron 16 mg orally and dexamethasone 10 mg IV push given 30 minutes prior to chemotherapy. The protocol was approved by the Scientifi c Review Committee at our center and the Institutional Review Board at the University of South Florida.
fi lgrastim). Eight of the 73 patients (11%) required a dose reduction in order to continue treatment with bendamustine. Hospitalization was required in 18 patients (24.6%), with median admission duration of 4 days. Hospitalization occurred secondary to FN in 9.5%, nonneutropenic fever in 8.2%, shortness of breath in 2.7%, abdominal pain/constipation in 1.3%, nausea/vomiting in 1.3%, and hypotension in 1.3%.
Bendamustine Administration and Discontinuation
Patients completed a median of 3 courses of therapy with bendamustine administration. The most common reasons for discontinuation were completion of therapy (23.2%), disease progression (13.6%), and myelosuppression (absolute neutrophil count < 1,000; 13.6%).
Other reasons for halting therapy with bendamustine included fatigue (6.8%) and infection (4.1%). These reported rates are consistent with those found in post-marketing experience with bendamustine. 7 However, we postulate the large number of patients discontinuing therapy secondary to disease progression may be a result of the heavily pretreated patient population.
Discussion
Based on our fi ndings, ondansetron and dexamethasone provide a safe and effective regimen for the prevention of IRRs associated with bendamustine use. Our premedication regimen has given providers a clear and concise standard for the prevention of IRRs while avoiding additional medications that could lead to unnecessary complications or adverse effects.
Remarkably, all IRRs were attributed to rituximab infusions, and no patients experienced an IRR when receiving bendamustine alone. This compares favorably to the initial reported IRRs when bendamustine is used alone (25%). Further studies are warranted to assess the incidence of FN in our diverse patient population and disease states as the utilization of bendamustine expands.
Our analysis was limited by the retrospective nature of our study, which confi ned us to the variables for which data were available. The incidence of nausea and vomiting was not consistently documented, and thus the presence of this adverse effect may not have been accurately captured, particularly while the patient was at home. Additionally, bendamustine IRRs can be delayed up to 24 hours; this information could not be consistently attained through a retrospective chart review. Notably, our data did include a heavily pretreated patient population, with nearly 50% receiving 3 or more previous treatments. In many instances the number of prior treatments can be correlated to the speed and effi ciency with which a patient may recover blood counts, specifi cally neutrophils. It is prudent to note the large proportion of captured patients who received bendamustine as a third-line (or greater) agent as this could imply a slightly higher incidence of growth factor use when compared to clinical trials in which bendamustine was often given as a second-or third-line agent. Additionally, the median patient age was 69 years, which, in combination with prior therapies, may have led to a vulnerable population. Twelve out of 34 patients experiencing any captured adverse effect to infusion were age 69 or older. Many of these patients were at a higher risk for treatment-related toxicities compared to the published literature and post-marketing surveillance. Another limitation of our study was the inability to accurately compare our data with that of other published series due to different sample sizes and other unaccounted variables. Finally, our relatively small population can lead to sampling error when comparing our single-center experience to multicenter experiences completed with a signifi cantly larger sample size.
Conclusions
Regardless of the potential limitations associated with this retrospective analysis, our fi ndings demonstrate that the premedication regimen that has been implemented at our institution compares favorably to published data with respect to the occurrence of IRRs and other adverse effects associated with bendamustine. Additionally, this allows avoidance of other premedications, thereby minimizing the likelihood of additional complications. The premedication regimen of ondansetron and dexamethasone has proven to be a safe and effective strategy for the prevention of IRRs with bendamustine administration and has been adopted as our institutional standard.
